Information Provided By:
Fly News Breaks for October 18, 2018
HALO
Oct 18, 2018 | 16:13 EDT
Piper Jaffray analyst Joseph Catanzaro assumed coverage of Halozyme Therapeutics with a Neutral rating and $17 price target. While the analyst views the Enhanze technology as an "attractive platform that could drive substantial royalty revenue," he has near term concerns around the pivotal HALO-301 study. He believes HALO-301 will need to hit on both progression-free survival and overall survival to support approval and adoption, which tempers his expectations.
News For HALO From the Last 2 Days
There are no results for your query HALO